Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Yamamoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, K.
Right arrow Articles by Yamamoto, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 60, 165-176 (2001)
Copyright © 2001 by the Society of Toxicology


SAFETY EVALUATION

Acute Canine Model for Drug-Induced Torsades de Pointes in Drug Safety Evaluation—Influences of Anesthesia and Validation with Quinidine and Astemizole

Keiji Yamamoto,1, Tomoko Tamura, Ryoetsu Imai and Masaki Yamamoto

Drug Safety Research Laboratories, Takeda Chemical Industries, Ltd., Drug Safety Research Labs, 17–85, Jusohonmachi 2–chome, Yodogawa–ku, Osaka 532-8686, Japan

An acute in vivo model for drug-induced torsades de pointes (TdP) for use in safety evaluation of drugs was developed using dogs with acute complete atrioventricular (AV) block. In order to study the effects of anesthetic agents on the inducibility of TdP, arrhythmias were induced by programmed electrical stimulation (PES) before and after cumulative intravenous administration of quinidine under anesthesia with sodium pentobarbital, halothane, or isoflurane. Both prolongation of the QTc and the incidence of TdP were greatest in dogs anesthetized with halothane and were smallest in those given pentobarbital, suggesting that halothane is the most suitable anesthetic for this TdP model. To further validate this model, astemizole was administered intravenously to other dogs under halothane anesthesia. Astemizole at 0.3 mg/kg caused slight prolongation of the QT interval but did not induce any arrhythmias. At 1 mg/kg, however, TdP were induced in 5 of 10 animals and in an additional 2 animals at 3 mg/kg. Single and multiple ectopic beats preceded the induction of TdP, and the ectopic beats were observed in a dose-dependent manner. The plasma concentrations of quinidine in dogs with TdP were equivalent to or less than quinidine levels in humans with TdP, while those of astemizole were higher in dogs. In conclusion, this acute canine model of TdP with halothane anesthesia, complete AV block, PES, and simultaneous measurements of plasma drug concentration would be valuable for assessing the risk of drugs, especially IKr blockers, to induce TdP in humans.

Key Words: torsades de pointes; dog model; astemizole; quinidine; anesthesia; drug safety.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Biomol ScreenHome page
A. Dorn, F. Hermann, A. Ebneth, H. Bothmann, G. Trube, K. Christensen, and C. Apfel
Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition
J Biomol Screen, June 1, 2005; 10(4): 339 - 347.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
C. Antzelevitch
Transmural dispersion of repolarization and the T wave
Cardiovasc Res, June 1, 2001; 50(3): 426 - 431.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.